Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

Core Insights - Corbus Pharmaceuticals Holdings, Inc. announced participation in several upcoming investor conferences, highlighting its commitment to engaging with the investment community [1][2][3] Company Overview - Corbus Pharmaceuticals is focused on oncology and obesity, with a diversified portfolio aimed at addressing serious illnesses through innovative scientific approaches [3] - The company's pipeline includes: - CRB-701: A next-generation antibody drug conjugate targeting Nectin-4 on cancer cells [3] - CRB-601: An anti-integrin monoclonal antibody that blocks TGFβ activation on cancer cells [3] - CRB-913: A peripherally restricted CB1 inverse agonist for obesity treatment [3] - Corbus is headquartered in Norwood, Massachusetts [3] Upcoming Conferences - B. Riley Securities Precision Oncology & Radiopharma Investor Conference on February 28, 2025, featuring a panel on Nectin-4 targeting therapies [2] - TD Cowen 45 Annual Health Care Conference on March 4, 2025, with a presentation scheduled [2] - Wedbush Securities Cardiometabolic Conference on March 10, 2025, focusing on alternative obesity targets [2] - Leerink Partners Global Healthcare Conference on March 12, 2025, including a presentation [3] - BMO 2025 Obesity Summit on March 25, 2025, discussing emerging technologies [3]